Story perspectives

FDA Recalls Subpotent Major Rugby Levothyroxine Tablets

7/28/2026

Summary

FDA Recall

The U.S. FDA announced a recall of Major Rugby’s levothyroxine sodium tablets because they are subpotent.
Major Rugby issued the recall on July 13, noting the affected tablets were shipped on Jan. 22, 2025.
The recall covers 12 prescription packages in strengths from 25 mcg to 150 mcg, including lot N02212 (exp. 07/2026).
Consumers should return the medication to the point of purchase or see a doctor.
The companies say adverse health effects are unlikely.

Summary

Manufacturers Recall

Subpotent levothyroxine tablets can leave patients under-treated, worsening fatigue, weight gain, cold intolerance, and cognitive issues.
Manufacturers issued recall notices by letter to consignees instead of a public press release.
Pharmacies receiving the lots must quarantine remaining inventory and follow standard recall procedures.
The recalled 10-count blister packs, sold singly or in cartons of ten, bear expiration dates from July 2026 through January 2027 and carry an FDA Class II designation indicating temporary, reversible effects with unlikely serious harm.

1 of 2

FDA Recall

The U.S. FDA announced a recall of Major Rugby’s levothyroxine sodium tablets because they are subpotent.
Major Rugby issued the recall on July 13, noting the affected tablets were shipped on Jan. 22, 2025.
The recall covers 12 prescription packages in strengths from 25 mcg to 150 mcg, including lot N02212 (exp. 07/2026).
Consumers should return the medication to the point of purchase or see a doctor.
The companies say adverse health effects are unlikely.

1 / 2